Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nadav Kidron | $619,529 | $379,935 | $3,709,269 | $0 | — | — | $65,927 | $4,774,660 |
| President, Chief Executive Officer and Chairman | ||||||||
| Joshua Hexter | 285,432 | 218,148 | 1,299,065 | 0 | — | — | 79,753 | 1,882,398 |
| Chief Operating and Business Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Nadav Kidron | $4,774,660 | — | — | — |
| Joshua Hexter | 1,882,398 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kidron | Option | 150,000 | 10.4 | — |
| Kidron | Option | 26,750 | 13.89 | — |
| Kidron | Option | 116,127 | 3.91 | — |
| Kidron | Option | 100,000 | 4.8 | — |
| Kidron | Option | 100,000 | 10.4 | — |
| Kidron | Option | 18,000 | 13.89 | — |
| Joshua Hexter | Option | 100,000 | 3.69 | — |
| Joshua Hexter | Option | 50,000 | 10.4 | — |
| Joshua Hexter | Option | 9,000 | 13.89 | — |
Our compensation philosophy is designed to provide the compensation and incentives needed to motivate and reward fairly those individuals who perform over time at or above the levels that we expect and to attract, as needed, and retain individuals with the skills necessary to achieve our objectives and who are crucial to our long-term success.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-08-01 | 9,171,779 | 1,016,334 | 74,388 | 90.02% | Passed |
| 2022 | 2022-06-30 | 10,073,933 | 1,100,188 | 106,011 | 90.15% | Passed |
| 2020 | 2020-08-03 | 7,275,546 | 299,671 | 188,778 | 96.04% | Passed |
| 2018 | 2018-08-28 | 3,661,606 | 889,122 | 31,149 | 80.46% | Passed |
| 2016 | 2016-08-30 | 2,970,134 | 117,293 | 1,228,900 | 96.2% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2024 | 2024-08-01 | 90.02%a |
| 2022 | 2022-06-30 | 90.15%b |
| 2020 | 2020-08-03 | 96.04%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dr. Daniel AghionIndependent · Compensation · Audit · Investment | $42,790 | $185,810 | $0 | — | $0 | $228,600 |
| Yehuda ReznickIndependent · Compensation · Audit · Investment | 42,790 | 185,808 | 0 | — | 0 | 228,598 |
| Dr. Arie MayerIndependent · Nominating and Corporate Governance · Audit | 40,000 | 178,961 | 0 | — | 0 | 218,961 |
| Benjamin ShapiroIndependent | 30,000 | 169,973 | 0 | — | 0 | 199,973 |
| Leonard SankIndependent · Compensation · Nominating and Corporate Governance · Departed during FY | 38,500 | 78,497 | 0 | — | 0 | 116,997 |
| Dr. Miriam KidronEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $30,000 |
|---|---|
| Annual equity retainer | $10,000 |
| Per board meeting fee | $500 |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $194,080 |
| Equity awards (grant-date value) | $799,049 |
| All other compensation | $0 |
| Total cost of the board | $993,129 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Oramed Pharmaceuticals | 2025 | Nadav Kidron | $619,529 | $3,709,269 | $0 | — | $4,774,660 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Nadav Kidron | DEF 14A | 2026-08-03 | 0001213900-26-084609 | Section “Executive Compensation”. As printed: 4,774,660. Filing ↗ |
| 2 | Section 01, Joshua Hexter | DEF 14A | 2026-08-03 | 0001213900-26-084609 | Section “Executive Compensation”. As printed: 1,882,398. Filing ↗ |
| 3 | Section 08, Dr. Daniel Aghion | DEF 14A | 2026-08-03 | 0001213900-26-084609 | Section “Director Compensation”. As printed: 228,600. Filing ↗machine: span 345960–345967 |
| 4 | Section 08, Yehuda Reznick | DEF 14A | 2026-08-03 | 0001213900-26-084609 | Section “Director Compensation”. As printed: 228,598. Filing ↗machine: span 356905–356912 |
| 5 | Section 08, Dr. Arie Mayer | DEF 14A | 2026-08-03 | 0001213900-26-084609 | Section “Director Compensation”. As printed: 218,961. Filing ↗machine: span 351425–351432 |
| 6 | Section 08, Benjamin Shapiro | DEF 14A | 2026-08-03 | 0001213900-26-084609 | Section “Director Compensation”. As printed: 199,973. Filing ↗machine: span 362367–362374 |
| 7 | Section 08, Leonard Sank | DEF 14A | 2026-08-03 | 0001213900-26-084609 | Section “Director Compensation”. As printed: 116,997. Filing ↗machine: span 367845–367852 |
| 8 | Section 08, Dr. Miriam Kidron | DEF 14A | 2026-08-03 | 0001213900-26-084609 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 9 | Section 06, 2024 vote | Form 8-K | 2024-08-02 | 0001213900-24-064732 | Item 5.07 · say-on-pay result. As reported: 90.02% (votes for as printed: 9,171,779). Filing ↗ |
| 10 | Section 06, 2022 vote | Form 8-K | 2022-06-30 | 0001213900-22-036294 | Item 5.07 · say-on-pay result. As reported: 90.15% (votes for as printed: 10,073,933). Filing ↗ |
| 11 | Section 06, 2020 vote | Form 8-K | 2020-08-04 | 0001213900-20-020031 | Item 5.07 · say-on-pay result. As reported: 96.04% (votes for as printed: 7,275,546). Filing ↗ |
| 12 | Section 09b board cost (computed) | Computed | — | computed | Cash 194,080 + equity 799,049 + all other 0 = 993,129, summed across the director compensation table rows.machine: formula: Σ = 993,129 |
| 13 | Oramed Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-08-03 | 0001213900-26-084609 | CEO total compensation as printed in Oramed Pharmaceuticals's own proxy. As printed: 4,774,660. Filing ↗ |